Jacobs Levy Equity Management, Inc Aprea Therapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

$24.7 Billion
Q3 2024

Shares

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 14, 2022	SELL	$2.87 - $5.58 $152,686 - $296,861	-53,201 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.43 - $5.63 $354,926 - $582,575	-103,477 Reduced 66.04%	53,201 $272,000
Q2 2021 Aug 16, 2021	SELL	$4.05 - $5.5 $176,891 - $240,223	-43,677 Reduced 21.8%	156,678 $765,000
Q1 2021 May 17, 2021	BUY	$4.73 - $8.15 $947,679 - $1.63 Million	200,355 New	200,355 $1.02 Million

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,921
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.